Wells Fargo & Company Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective dropped by Wells Fargo & Company from $10.00 to $6.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 100.00% from the company’s previous close.

HCAT has been the subject of several other research reports. Stifel Nicolaus decreased their price objective on Health Catalyst from $5.50 to $4.50 and set a “hold” rating for the company in a report on Friday, August 8th. BTIG Research lowered Health Catalyst from a “buy” rating to a “neutral” rating in a report on Tuesday, June 17th. KeyCorp lowered their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Canaccord Genuity Group cut their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, Citigroup lowered shares of Health Catalyst from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $6.50 to $3.50 in a report on Friday, August 8th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.18.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $3.00 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.24. The firm has a 50-day moving average of $3.80 and a 200-day moving average of $4.22. Health Catalyst has a one year low of $2.52 and a one year high of $9.24. The company has a market cap of $208.80 million, a P/E ratio of -1.99 and a beta of 1.46.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently made changes to their positions in HCAT. SG Americas Securities LLC lifted its position in Health Catalyst by 195.2% during the 1st quarter. SG Americas Securities LLC now owns 80,825 shares of the company’s stock valued at $366,000 after acquiring an additional 53,443 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Health Catalyst in the 4th quarter worth approximately $735,000. Wells Fargo & Company MN grew its stake in shares of Health Catalyst by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,355 shares of the company’s stock worth $278,000 after buying an additional 8,451 shares during the last quarter. Two Sigma Investments LP bought a new position in Health Catalyst during the 4th quarter valued at approximately $496,000. Finally, Northern Trust Corp raised its stake in Health Catalyst by 8.5% during the fourth quarter. Northern Trust Corp now owns 526,607 shares of the company’s stock valued at $3,723,000 after buying an additional 41,298 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.